ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Metformin

Also written as “metformin”, “Metformin XR” and “Fenofibrate /Metformin”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Obesity · Fasting · Polycystic Ovary Syndrome, led by 48 companies.

Drug pageMetformin: every studyMany companies study it; this page follows only the 215 they lead. All 1,290 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 9, 2005215 company-led studies, 7 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only290 open or runningphase 3since Nov 9, 2005Nov 9, 2005none ahead
Merck190 open or runningphase 4since Oct 9, 2009Feb 15, 2005none ahead
Sanofiits history only160 open or runningphase 4since Jul 28, 2006Sep 30, 2002none ahead
GlaxoSmithKlineits history only140 open or runningphase 4since Oct 17, 2005Sep 3, 2003none ahead
Takedaits history only120 open or runningphase 4since Sep 17, 2008Jul 30, 2008none ahead
Merck KGaA, Darmstadt, Germanyits history only90 open or runningphase 4since Dec 30, 2011Dec 30, 2011none ahead
Teva Pharmaceutical Industriesits history only90 open or runningphase 1since Jan 30, 2009Jan 30, 2009none ahead
Viatrisits history only80 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
ADIUMits history only70 open or runningno phasesince Jun 3, 2026Jun 3, 2026none ahead
LG Chemits history only70 open or runningphase 3since Feb 6, 2013Aug 22, 2011none ahead

Also a collaborator on its studies: Parexel, PT Pharma Metric Labs, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene, Eli Lilly and Merck, S.L., Spain.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Feb 15, 2005.

  1. Feb 21, 2008Phase 2 study in Diabetes Mellitus, Type 2NCT00631488 · 146 enrolled
  2. Jan 26, 2009Phase 1 study in Diabetes Mellitus, Type 2NCT00830076 · 18 enrolled
  3. Jun 25, 2009Phase 1 study in Diabetes Mellitus, Type 2NCT00929201 · 61 enrolled
  4. Oct 9, 2009Phase 4 study in Diabetes Mellitus, Type 2NCT00993187 · 292 enrolled
  5. Dec 16, 2009Phase 3 study in Diabetes Mellitus, Type 2NCT01034111 · 30 enrolled
  6. Feb 24, 2010Phase 3 study in Diabetes Mellitus, Type 2NCT01076088 · 744 enrolled
  7. Mar 19, 2010Phase 1 study in Diabetes Mellitus, Type 2NCT01093794 · 28 enrolled
  8. Mar 1, 2012Phase 3 study in Diabetes Mellitus, Type 2NCT01545388 · 337 enrolled
  9. Mar 16, 2012Phase 1 study in Diabetes Mellitus, Type 2NCT01557504 · 25 enrolled
  10. Oct 4, 2012Phase 3 study in Diabetes Mellitus, Type 2NCT01702298 · 42 enrolled
  11. Jan 2, 2013Phase 3 study in Diabetes Mellitus, Type 2NCT01760447 · 223 enrolled
  12. Aug 12, 2025Phase 1 study in HealthyNCT07121959 · 14 enrolled · United States
  13. Oct 27, 2025Phase 1 study in HealthyNCT07222098 · 16 enrolled · United States
  14. Apr 7, 2026Phase 1 study in HealthyNCT07530289 · 12 enrolled · United States

TargetBeta

“Mitochondrial complex I (NADH dehydrogenase) inhibitor; Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor”ChEMBL 37, by rule

Studies

All 19 Merck leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07530289Healthy · United States1CompletedMay 23, 202612
NCT07222098Healthy · United States1CompletedDec 14, 202516
NCT07121959Healthy · United States1CompletedSep 13, 202514
NCT01760447Diabetes Mellitus, Type 23CompletedSep 17, 2019223
NCT01702298Diabetes Mellitus, Type 23CompletedMay 29, 201342
NCT01557504Diabetes Mellitus, Type 21CompletedApr 29, 201425
NCT01545388Diabetes Mellitus, Type 23CompletedMar 12, 2013337
NCT01093794Diabetes Mellitus, Type 21CompletedJun 201028
NCT01076088Diabetes Mellitus, Type 23CompletedDec 24, 2012744
NCT01034111Diabetes Mellitus, Type 23CompletedOct 4, 201030
NCT00993187Diabetes Mellitus, Type 24CompletedOct 29, 2013292
NCT00929201Diabetes Mellitus, Type 21CompletedMar 200861
NCT00830076Diabetes Mellitus, Type 21CompletedApr 30, 200918
NCT00631488Diabetes Mellitus, Type 22CompletedJan 2009146
NCT00543361Diabetes Mellitus, Type 23TerminatedDec 2003382
NCT00541450Diabetes Mellitus, Type 23CompletedJan 8, 2010492
NCT00532935Diabetes Mellitus, Type 23CompletedOct 23, 2009517
NCT00482729Diabetes Mellitus, Type 23CompletedNov 3, 20081,246
NCT00103857Diabetes Mellitus, Type 23CompletedJul 25, 20061,208

How it is read

Names in the registry

  • “Metformin”, 95 entries
  • “metformin”, 33 entries
  • “Metformin XR”, 11 entries
  • “Fenofibrate /Metformin”, 6 entries
  • “Sitagliptin/Metformin FDC”, 5 entries

Codes read as this program: EFB0027.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.